RxDoctor Payments Data

Molly Williams

Nurse Practitioner · Kansas City, MONPI 1457866253

Payments from drug & device makers

$4,534in general payments, 2019–2025

Across 216 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$735
  • Pfizer$413
  • Novo Nordisk$379
  • Novartis$368
  • Amgen$304
  • Organogenesis Inc.$279
  • plus $2K from 26 others

What the payments were for

  • Travel & lodging$2916%
  • Food & beverage$4,10090%
  • Education$1423%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,534 in reported general payments places this provider in the 90th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$13,268
Medicare patients
110
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan15$29,837
JardianceEmpagliflozin27$29,532
EliquisApixaban11$10,953
Metoprolol Succinate59$672
Rosuvastatin Calcium27$630
Atorvastatin Calcium63$526
Losartan Potassium47$369
Spironolactone33$238
Ezetimibe13$188
Carvedilol30$180
Furosemide33$168
ClopidogrelClopidogrel Bisulfate24$129
Isosorbide Mononitrate ErIsosorbide Mononitrate13$96
Amlodipine Besylate22$85
Hydrochlorothiazide12$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$368$29,83715 claims
Boehringer IngelheimJardiance$263$29,53227 claims
PfizerEliquis$413$10,95311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →